Loading...
Market
Story
Recordati Acquires Sanofi's Enjaymo for Rare Disease CAD in $1 Billion Deal; Shares Jump
Oct 4, 2024, 10:45 AM
Recordati, an Italian pharmaceutical company, announced on Friday that it will acquire the global rights to Enjaymo, a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, from Sanofi for $825 million upfront with potential contingent payments of $250 million, bringing the total deal value up to $1 billion. The acquisition strengthens Recordati's rare diseases franchise and sent both companies' stocks higher in early trading, with Recordati shares jumping on the news. Enjaymo has current sales of approximately €150 million and projected sales estimated at €250-300 million.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $20 million • 25%
$20 million to $25 million • 25%
$25 million to $30 million • 25%
More than $30 million • 25%